Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIM0278 in Active Lupus Nephritis
NCT07393451Phase 2Not yet recruiting
- Sponsor
- Simcere Pharmaceutical Group
- Start
- Mar 2026
- Primary completion
- Mar 2028
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of SIM0278 in lupus nephritis (LN), sponsored by Simcere Pharmaceutical Group. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
SIM0278
03
Conditions
lupus nephritis (LN)
Beyond the preview
Go deeper on NCT07393451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07393451.